GILD · Gilead Sciences, Inc.
$139.712026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$135
-3.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($125 · $188) Analysts Range ($105 · $180) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $27.3B | — | 41.1% | 25.1% | $8.4B | −$751MM | $7.7B | 3.9% | — | 15.3% | $54.8B | $4.97 | — |
| 2022.Q4 | $27.3B | -0.1% | 30.4% | 21.5% | $6.5B | −$3.5B | $3.1B | 5.7% | — | 11.9% | $54.7B | $3.66 | — |
| 2023.Q4 | $27.1B | -0.6% | 31.7% | 18.2% | $7.0B | −$2.8B | $4.2B | 5.6% | — | 12.7% | $56.4B | $4.52 | — |
| 2024.Q4 | $28.8B | 6.0% | 6.5% | 30.6% | $1.3B | −$5.0B | −$3.7B | 6.3% | — | 2.4% | $52.0B | $0.38 | — |
| 2025.Q4 | $29.4B | 2.4% | 42.3% | 13.1% | $10.8B | −$4.3B | $6.5B | 6.0% | — | 20.5% | $53.4B | $6.79 | 14.1 |
| italics below = DCF projection · 10yr Rev CAGR: 4.8% |
| 2026.Q4 | $30.2B | +2.6% | 47.8% | 13.8% | $12.5B | −$1.4B | $11.0B | 6.2% | $10.4B | 23.0% | $54.8B | $7.77 | 18.0 |
| 2027.Q4 | $32.1B | +6.2% | 45.4% | 14.5% | $12.4B | −$3.6B | $8.9B | 6.5% | $7.9B | 22.0% | $58.4B | $7.92 | 17.6 |
| 2028.Q4 | $33.8B | +5.2% | 42.9% | 15.2% | $12.3B | −$3.3B | $9.0B | 6.7% | $7.5B | 20.5% | $61.7B | $7.98 | 17.5 |
| 2029.Q4 | $35.8B | +6.1% | 40.4% | 15.9% | $12.2B | −$4.2B | $8.0B | 6.9% | $6.2B | 19.1% | $65.8B | $8.11 | 17.2 |
| 2030.Q4 | $37.7B | +5.3% | 35.4% | 16.6% | $11.1B | −$3.9B | $7.2B | 7.2% | $5.2B | 16.4% | $69.7B | $7.86 | 17.8 |
|
| Term. Yr+ | $49.1B | 4.1% | 35.4% | 20.0% | $13.9B | −$4.4B | $9.6B | 8.6% | $105.1B | 13.1% | — | — | — |
Active scenario IV: $135 (-3.7% vs market)